Page last updated: 2024-12-06

norchlorpromazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

norchlorpromazine: active metabolite of chlorpromazine; RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID62875
CHEMBL ID825
CHEBI ID125597
MeSH IDM0094559

Synonyms (33)

Synonym
norchlorpromazine
CHEBI:125597
CHEMBL825 ,
nor1-chlorpromazine
3-(2-chlorophenothiazin-10-yl)-n-methylpropan-1-amine
o1g7lw1i5h ,
n-desmethylchlorpromazine
1225-64-5
unii-o1g7lw1i5h
10h-phenothiazine-10-propanamine, 2-chloro-n-methyl-
n-monodesmethylchlorpromazine
bdbm50408489
BRD-K58901278-001-01-8
nor1chlorpromazine
monodesmethylchlorpromazine
ba-2837
nor1-cpz
demethylchlorpromazine
chlorpromazine hydrochloride impurity d [ep impurity]
3-(2-chloro-10h-phenothiazin-10-yl)-n-methylpropan-1-amine
YHFXGBOUSIKGMZ-UHFFFAOYSA-N
desmethylchloropromazine
Q27216212
DTXSID50153631
STL454166
chlorpromazine-m norl
demonomethylchlorpromazine
desmethylchlorpromazine; 3-(2-chloro-10h-phenothiazin-10-yl)-n-methylpropan-1-amine; demethyl chlorpromazine; 2-chloro-n-methyl-10h-phenothiazine-10-propanamine
chlorpromazine ep impurity d
3-(2-chlorophenothiazin-10-yl)-n-methyl-propan-1-amine
A899014
chlorpromazine impurity d
10h-phenothiazine-10-propanamine,2-chloro-n-methyl-

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
"Thirty-seven newly admitted schizophrenic patients were treated with an open and flexible dosage of chlorpromazine for 3 months after receiving a test dose."( Prediction of drug responses in schizophrenia: a method using a test dose of chlorpromazine.
Minami, H; Miyahara, A; Nakahara, T; Nakane, Y, 1997
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phenothiazines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Trypanothione reductaseTrypanosoma cruziIC50 (µMol)126.00005.80005.80005.8000AID214488
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (12)

Assay IDTitleYearJournalArticle
AID214488Inhibitory activity against recombinant Trypanosoma cruzi (Trypanosoma cruzi) Trypanothione reductase1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
AID75299Inhibitory activity against human erythrocyte glutathione reductase; '*' indicates No inhibition1998Journal of medicinal chemistry, Jan-15, Volume: 41, Issue:2
Phenothiazine inhibitors of trypanothione reductase as potential antitrypanosomal and antileishmanial drugs.
AID1182134Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of kanamycin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182148Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of 25-desacetylrifampicin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182149Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of kanamycin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182150Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of spectinomycin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182135Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of spectinomycin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID103232Anti MDR activity was expressed as MDR ratio or MDR fold reversal in doxorubicin resistant human breast carcinoma tumor cell line MCF-7/DOX1998Journal of medicinal chemistry, May-21, Volume: 41, Issue:11
Molecular modeling of phenothiazines and related drugs as multidrug resistance modifiers: a comparative molecular field analysis study.
AID1182131Antitubercular activity against Mycobacterium smegmatis by checkerboard assay2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182146Ratio of MIC99 for Mycobacterium smegmatis to ratio of MIC99 for Mycobacterium smegmatis in presence of rifampicin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182133Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of 25-desacetylrifampicin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
AID1182132Antitubercular activity against Mycobacterium smegmatis by checkerboard assay in presence of rifampicin2014Bioorganic & medicinal chemistry, Aug-15, Volume: 22, Issue:16
Pharmacologically active metabolites, combination screening and target identification-driven drug repositioning in antituberculosis drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19909 (60.00)18.7374
1990's4 (26.67)18.2507
2000's0 (0.00)29.6817
2010's1 (6.67)24.3611
2020's1 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 11.69

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index11.69 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.58 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (11.69)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (13.33%)5.53%
Reviews1 (6.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (80.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]